Entera Bio Ltd (ENTX)

Currency in USD
2.050
-0.080(-3.76%)
Closed·
2.0500.000(0.00%)
·
Earnings results expected in 11 days
ENTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.0002.170
52 wk Range
0.9103.220
Key Statistics
Prev. Close
2.13
Open
2.13
Day's Range
2-2.17
52 wk Range
0.91-3.22
Volume
163.47K
Average Volume (3m)
1.03M
1-Year Change
10.2151%
Book Value / Share
0.23
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ENTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
9.000
Upside
+339.02%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Entera Bio Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 9.000
(+339.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy9.00+339.02%-MaintainJun 24, 2026
H.C. Wainwright
Buy9.00+339.02%10.00MaintainApr 27, 2026
H.C. Wainwright
Buy10.00+387.80%-MaintainDec 24, 2025
H.C. Wainwright
Buy10.00+387.80%-MaintainSep 25, 2025

Earnings

Latest Release
May 08, 2026
EPS / Forecast
-0.07 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ENTX Income Statement

Compare ENTX to Peers and Sector

Metrics to compare
ENTX
Peers
Sector
Relationship
P/E Ratio
−8.2x−3.6x−0.4x
PEG Ratio
4.15−0.040.00
Price/Book
9.5x1.6x2.6x
Price / LTM Sales
-33.2x2.9x
Upside (Analyst Target)
339.0%530.5%58.0%
Fair Value Upside
Unlock23.3%9.5%Unlock

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
178.58K0.36%366.08K
Other Institutional Investors
12.22M24.79%25.05M
Public Companies & Retail Investors
36.89M74.85%75.63M
Total
49.29M100.00%101.04M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Knoll Capital Management8.09%3,989,0678,178
OPKO Health, Inc.7.48%3,685,2267,555

People Also Watch

1.700
GDC
-2.30%
0.385
IMMP
-2.04%
90.26
NICE
+3.96%
1.570
CRBU
-3.68%

FAQ

What Is the Entera Bio (ENTX) Stock Price Today?

The Entera Bio stock price today is 2.050 USD.

What Stock Exchange Does Entera Bio Trade On?

Entera Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Entera Bio?

The stock symbol for Entera Bio is "ENTX."

What Is the Entera Bio Market Cap?

As of today, Entera Bio market cap is 101.040M USD.

What Is Entera Bio's Earnings Per Share (TTM)?

The Entera Bio EPS (TTM) is -0.262.

When Is the Next Entera Bio Earnings Date?

Entera Bio will release its next earnings report on Aug 07, 2026.

From a Technical Analysis Perspective, Is ENTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Entera Bio Stock Split?

Entera Bio has split 0 times.

How Many Employees Does Entera Bio Have?

Entera Bio has 21 employees.

What is the current trading status of Entera Bio (ENTX)?

As of Jul 27, 2026, Entera Bio (ENTX) is trading at a price of 2.050 USD, with a previous close of 2.130 USD. The stock has fluctuated within a day range of 2.000 USD to 2.170 USD, while its 52-week range spans from 0.910 USD to 3.220 USD.

What Is Entera Bio (ENTX) Price Target According to Analysts?

The average 12-month price target for Entera Bio is 9.000 USD, with a high estimate of 9 USD and a low estimate of 9 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +339.02% Upside potential.

What Is the ENTX Premarket Price?

ENTX's last pre-market stock price is 2.120 USD. The pre-market share volume is 249.000, and the stock has decreased by -0.010, or -0.470%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.